Cartesian Therapeutics reports significant improvement in myasthenia gravis patients, plans Phase 3 trial.
Cartesian Therapeutics reported positive results from a Phase 2b trial for Descartes-08, a treatment for myasthenia gravis, showing significant improvements in patients' daily living activities. Participants experienced a 5.5-point reduction in MG-ADL scores at four months, with responses lasting up to a year. The company's stock rose over 5% pre-market, and a Phase 3 study is planned for early 2025.
4 months ago
4 Articles
Further Reading
You have 6 free stories remaining this month. Subscribe anytime for unlimited access.